American Vanguard (AVD) 10-Q 2 May 14 2014 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2014	Apr. 24, 2014
Document Information [Line Items]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	31-Mar-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q1	'
Trading Symbol	'AVD	'
Entity Registrant Name	'AMERICAN VANGUARD CORP	'
Entity Central Index Key	'0000005981	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Large Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	28,749,722

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations and Comprehensive Income (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Net sales	$81,095	$121,537
Cost of sales	52,190	67,756
Gross profit	28,905	53,781
Operating expenses	24,943	27,628
Operating income	3,962	26,153
Interest expense	631	547
Less interest capitalized	-18	-194
Income before provision for income taxes and loss on equity investment	3,349	25,800
Income taxes expense	1,016	8,981
Income before loss on equity investment	2,333	16,819
Deduct net loss from equity method investment	-328	'
Net income	2,005	16,819
Add back net loss attributable to non-controlling interest	154	96
Net income attributable to American Vanguard	2,159	16,915
Change in fair value of interest rate swaps	136	178
Foreign currency translation adjustment	51	407
Comprehensive income	$2,346	$17,500
Earnings per common share - basic	$0.08	$0.60
Earnings per common share - assuming dilution	$0.07	$0.59
Weighted average shares outstanding - basic	28,401	28,269
Weighted average shares outstanding - assuming dilution	28,888	28,879

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$8,391	$6,680
Receivables:	'	'
Trade, net of allowance for doubtful accounts of $429 and $392, respectively	103,391	74,060
Other	2,501	892
Total receivables	105,892	74,952
Inventories	158,459	139,830
Prepaid expenses	12,543	11,435
Income taxes receivable	9,628	10,088
Deferred income tax assets	6,521	6,521
Total current assets	301,434	249,506
Property, plant and equipment, net	52,148	52,468
Intangible assets, net of applicable amortization	105,442	107,007
Other assets	39,070	38,462
Total assets	498,094	447,443
Current liabilities:	'	'
Current installments of long-term debt	70	69
Current installments of other liabilities	1,388	2,132
Accounts payable	40,185	40,702
Deferred revenue	1,479	3,788
Accrued program costs	61,956	53,630
Accrued expenses and other payables	7,036	10,178
Total current liabilities	112,114	110,499
Long-term debt, excluding current installments	99,108	51,676
Other liabilities, excluding current installments	4,482	4,143
Deferred income tax liabilities	23,330	23,330
Total liabilities	239,034	189,648
Commitments and contingent liabilities	'	'
Stockholders' equity:	'	'
Preferred stock, $.10 par value per share; authorized 400,000 shares; none issued	'	'
Common stock, $.10 par value per share; authorized 40,000,000 shares; issued 31,190,906 shares at March 31, 2014 and 31,092,782 shares at December 31, 2013	3,119	3,109
Additional paid-in capital	62,171	60,160
Accumulated other comprehensive loss	-861	-1,048
Retained earnings	203,212	202,470
Total stockholders' equity including treasury stock	267,641	264,691
Less treasury stock at cost, 2,450,634 shares at March 31, 2014 and 2,380,634 shares at December 31, 2013	-8,269	-6,738
American Vanguard Corporation stockholders' equity	259,372	257,953
Non-controlling interest	-312	-158
Total stockholders' equity	259,060	257,795
Total liabilities and stockholders' equity	$498,094	$447,443

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, except Share data, unless otherwise specified
Allowance for doubtful accounts	$429	$392
Preferred stock, par value per share	$0.10	$0.10
Preferred stock, shares authorized	400,000	400,000
Preferred stock, shares issued	'	'
Common stock, par value per share	$0.10	$0.10
Common stock, shares authorized	40,000,000	40,000,000
Common stock, shares issued	31,190,906	31,092,782
Treasury stock, shares	2,450,634	2,380,634

Condensed_Consolidated_Stateme1

Condensed Consolidated Statement of Stockholders' Equity (USD $)	Total	Common Stock	Additional Paid-in Capital	Retained Earnings	Accumulated Other Comprehensive loss	Non- Controlling Interest	Treasury Stock
In Thousands, except Share data
Beginning Balance at Dec. 31, 2013	$257,795	$3,109	$60,160	$202,470	($1,048)	($158)	($6,738)
Beginning Balance (in shares) at Dec. 31, 2013	31,092,782	31,092,782	'	'	'	'	2,380,634
Stocks issued under ESPP (in shares)	'	16,446	'	'	'	'	'
Stocks issued under ESPP	393	2	391	'	'	'	'
Cash dividends on common stock	-1,417	'	'	-1,417	'	'	'
Foreign currency translation adjustment, net	51	'	'	'	51	'	'
Stock based compensation	768	'	768	'	'	'	'
Change in fair value of interest rate swaps	136	'	'	'	136	'	'
Stock options exercised and grants of restricted stock units	625	8	617	'	'	'	'
Stock options exercised and grants of restricted stock units, Shares	'	81,678	'	'	'	'	'
Excess tax benefits from share based payment arrangements	235	'	235	'	'	'	'
Shares repurchased (in shares)	'	'	'	'	'	'	70,000
Shares repurchased	-1,531	'	'	'	'	'	-1,531
Net income (loss)	2,005	'	'	2,159	'	-154	'
Ending Balance at Mar. 31, 2014	$259,060	$3,119	$62,171	$203,212	($861)	($312)	($8,269)
Ending Balance (in shares) at Mar. 31, 2014	31,190,906	31,190,906	'	'	'	'	2,450,634

Condensed_Consolidated_Stateme2

Condensed Consolidated Statement of Stockholders' Equity (Parenthetical) (USD $)	3 Months Ended
	Mar. 31, 2014
Cash dividends on common stock, per share	$0.05

Condensed_Consolidated_Stateme3

Condensed Consolidated Statements of Cash Flows (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Cash flows from operating activities:	'	'
Net income	$2,005	$16,819
Adjustments to reconcile net income to net cash used in operating activities:	'	'
Depreciation and amortization of fixed and intangible assets	3,733	3,699
Amortization of other long term assets	1,454	836
Amortization of discounted liabilities	69	42
Stock-based compensation	768	688
Tax benefit from exercise of stock options	-235	-57
Loss from equity method investment	328	'
Gain on dilution of equity method investment	-256	'
Changes in assets and liabilities associated with operations:	'	'
Increase in net receivables	-30,940	-70,908
Increase in inventories	-18,629	-21,538
Increase in prepaid expenses and other assets	-3,242	-7,027
Decrease in income tax receivable/payable, net	695	6,108
(Decrease) increase in accounts payable	-381	31,250
Decrease in deferred revenue	-2,309	-18,148
Increase in other payables and accrued expenses	5,050	40,100
Net cash used in operating activities	-41,890	-18,136
Cash flows from investing activities:	'	'
Capital expenditures	-1,816	-4,396
Investment	'	-3,687
Net cash used in investing activities	-1,816	-8,083
Cash flows from financing activities:	'	'
Net borrowings under line of credit agreement	47,450	6,200
Payments on long-term debt	'	-2,500
Payments on other long-term liabilities	-356	-682
Tax benefit from exercise of stock options	235	57
Decrease in other notes payable	'	-6,154
Repurchases of common stock	-1,531	'
Proceeds from the issuance of common stock (sale of stock under ESPP and exercise of stock options)	1,018	427
Payment of cash dividends	-1,418	'
Net cash provided (used) by financing activities	45,398	-2,652
Net increase (decrease) in cash and cash equivalents	1,692	-28,871
Cash and cash equivalents at beginning of period	6,680	38,476
Effect of exchange rate changes on cash	19	390
Cash and cash equivalents as of the end of the period	$8,391	$9,995

Summary_of_Significant_Account

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2014
Summary of Significant Accounting Policies	'
	1. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation, have been included. Operating results for the three months ended March 31, 2014 are not necessarily indicative of the results that may be expected for the year ending December 31, 2014. For further information, refer to the condensed consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013.
	The preparation of the condensed consolidated financial statements, in conformity with accounting principles generally accepted in the United States of America, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities. It also requires management to make estimates and assumptions on the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reported periods. Actual results could differ from those estimates.

Property_plant_and_equipment

Property, plant and equipment	3 Months Ended
	Mar. 31, 2014
Property, plant and equipment	'
	2. Property, plant and equipment at March 31, 2014 and December 31, 2013 consists of the following:
		March 31,			December 31,
		2014			2013
	Land	$	2,458		$	2,458
	Buildings and improvements		14,237			14,167
	Machinery and equipment		97,124			94,184
	Office furniture, fixtures and equipment		9,932			9,717
	Automotive equipment		288			278
	Construction in progress		9,196			10,615
			133,235			131,419
	Less accumulated depreciation		(81,087	)		(78,951	)
		$	52,148		$	52,468

Inventories

Inventories	3 Months Ended
	Mar. 31, 2014
Inventories	'
	3. Inventories are stated at the lower of cost or market. Cost is determined using the first-in, first-out method. The components of inventories consist of the following:
		March 31,		December 31,
		2014		2013
	Finished products	$	144,450	$	126,872
	Raw materials		14,009		12,958
		$	158,459	$	139,830

Segment_Reporting

Segment Reporting	3 Months Ended
	Mar. 31, 2014
Segment Reporting	'
	4. Based on similar economic and operational characteristics, the Company’s business is aggregated into one reportable segment. Selective enterprise information is as follows:
		Three Months Ended
		March 31
		2014		2013
	Net sales:
	Insecticides	$	46,437	$	78,867
	Herbicides/soil fumigants/fungicides		22,931		32,986
	Other, including plant growth regulators		3,807		3,691
			73,175		115,544
	Non-crop		7,920		5,993
		$	81,095	$	121,537
		Three Months Ended
		March 31
		2014		2013
	Net sales:
	US sales	$	57,956	$	103,105
	International sales		23,139		18,432
		$	81,095	$	121,537

Accrued_Program_Costs

Accrued Program Costs	3 Months Ended
	Mar. 31, 2014
Accrued Program Costs	'
	5. Accrued Program Costs - In accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 605, the Company classifies certain payments to its customers as a reduction of sales. The Company describes these payments as “Programs.” Programs are a critical part of doing business in the agricultural chemicals business market place. For accounting purposes, programs are recorded as a reduction in gross sales and include market pricing adjustments, volume take up or other key performance indicator-driven payments made to distributors, retailers or growers at the end of a growing season. Each quarter management compares each sale transaction with published programs to determine what program liability has been incurred. Once this initial calculation is made for the specific quarter, sales and marketing management along with executive and financial management review the accumulated program balance and make assessments of whether or not customers are tracking in a manner that indicates that they will meet the requirements set out in the terms and conditions attached to each program. If management believes that customers are falling short of their annual goals then periodic adjustments will be made to the accumulated accrual to properly reflect the Company’s best estimate of the liability at the balance sheet date. The majority of adjustments are made at the end of the crop season, at which time customer performance can be fully assessed. Programs are paid out predominantly on an annual basis, usually in the final quarter of the financial year or the first quarter of the following year.

Cash_Dividends

Cash Dividends	3 Months Ended
	Mar. 31, 2014
Cash Dividends	'
	6. On March 10, 2014, the Board of Directors declared a cash dividend of $0.05 per share. The dividend was distributed on April 18, 2014 to stockholders of record at the close of business on April 4, 2014. Cash dividends paid April 18, 2014 totaled $1,417.
	On March 11, 2013, the Board of Directors declared a cash dividend of $0.07 per share. The dividend was distributed on April 19, 2013 to stockholders of record at the close of business on April 5, 2013. Cash dividends paid April 19, 2013 totaled $1,976.
	The Company announced the decision to begin making quarterly dividend payments on June 10, 2013. Previously, the Company made semi-annual dividend payments.

Earnings_Per_Share

Earnings Per Share	3 Months Ended
	Mar. 31, 2014
Earnings Per Share	'
	7. Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 260 Earnings Per Share (“EPS”) requires dual presentation of basic EPS and diluted EPS on the face of our condensed consolidated statements of operations and comprehensive income. Basic EPS is computed as net income divided by the weighted average number of shares of common stock outstanding during the period. Diluted EPS reflects potential dilution that could occur if securities or other contracts, which, for the Company, consists of options to purchase shares of the Company’s common stock are exercised.
	The components of basic and diluted earnings per share were as follows:
		Three Months Ended
		March 31,
		2014		2013
	Numerator:
	Net income attributable to American Vanguard	$	2,159	$	16,915
	Denominator:
	Weighted averages shares outstanding-basic		28,401		28,269
	Dilutive effect of stock options and grants		487		610
			28,888		28,879

Indebtedness

Indebtedness	3 Months Ended
	Mar. 31, 2014
Indebtedness	'
	8. Substantially all of the Company’s assets are pledged as collateral with its banks.
	The Company has a revolving line of credit and various notes payable that together constitute the short-term and long-term loan balances shown in the condensed consolidated balance sheets at March 31, 2014 and December 31, 2013. These are summarized in the following table:
	Indebtedness	March 31, 2014									December 31, 2013
	$000’s	Long-			Short-			Total			Long-			Short-			Total
		term			term						term			term
	Revolving line of credit	$	99,000		$	—		$	99,000		$	51,550		$	—		$	51,550
	Notes payable		108			70			178			126			69			195
	Total Indebtedness	$	99,108		$	70		$	99,178		$	51,676		$	69		$	51,745
	On June 17, 2013, AMVAC Chemical Corporation (“AMVAC”), the Company’s principal operating subsidiary, as borrower, and affiliates (including the Company), as guarantors and/or borrowers, entered into a Second Amended and Restated Credit Agreement (the “New Credit Agreement”) with a group of commercial lenders led by Bank of the West (AMVAC’s primary bank) as agent, swing line lender and L/C issuer. The new facility also includes both AMVAC C.V. and AMVAC Netherlands BV (both Dutch subsidiaries) as borrowers. The New Credit Agreement supersedes the Amended and Restated Credit Agreement (“First Amendment”) dated as of January 10, 2011. The New Credit Agreement is a senior secured lending facility with a five year term and consists of a revolving line of credit up to $200 million and an accordion feature for up to $100 million. In connection with AMVAC’s entering into the New Credit Agreement, all outstanding indebtedness under the First Amendment was rolled over into the New Credit Agreement, including the conversion of term loans into revolving debt.
	At March 31, 2014, the Company had in place one interest rate swap contract with a notional amount of $34,875 that is accounted for under FASB ASC 815 as a cash flow hedge. The effective portion of the gains or losses on the interest rate swap are reported as a component of other comprehensive income and reclassified into earnings in the same period or periods during which the hedged transactions affect earnings. Losses in other comprehensive income expected to be reclassified to earnings in the coming 12 months are $(204). Amounts recorded in earnings for hedge ineffectiveness for the period ending March 2014 were immaterial.
	The Company uses a pay fixed, receive 1Month LIBOR (London Interbank Offered Rate) interest rate swap to manage the interest expense generated by variable rate debt. At March 31, 2014 and 2013, the Company had in place an interest rate swap, the use of which results in a fixed interest rate of 3.39% for the portion of variable rate debt that is covered by the interest rate swap contract. The current interest rate swap contract was put in place on March 30, 2011 and terminates on December 31, 2014.
	The following tables illustrate the impact of derivatives on the Company’s statement of operations for the quarter ended March 31, 2014.
	The Effect of Derivative Instruments on the Statement of Financial Performance
	For the Period Ended March 31
	Derivatives in ASC 815 Cash Flow	Amount of Gain or						Location of Gain or			Amount of Gain or (Loss)						Location of Gain or		Amount of Gain or
	Hedging Relationships	(Loss) Recognized in						(Loss) Reclassified			Reclassified from Accumulated						(Loss) Recognized in		(Loss)
		OCI on Derivative						from Accumulated			OCI into Income (Effective						Income on Derivative		Recognized
		(Effective Portion)						OCI into Income			Portion)						(Ineffective Portion)		in Income on
								(Effective Portion)											Derivative
																			(Ineffective Portion)
		2014			2013						2014			2013					2014		2013
	Interest rate contracts	$	(23	)	$	(7	)		Interest Expense		$	(159	)	$	(185	)	Interest Expense		$	—	$	—
	Total	$	(23	)	$	(7	)				$	(159	)	$	(185	)			$	—	$	—
	The Company has three key covenants to its senior, secured credit facility with its banking syndicate. The covenants are as follows: (1) the Company must maintain its borrowings below a certain consolidated funded debt ratio, (2) the Company has a limitation on its annual spending on the acquisition of fixed asset capital additions, and (3) the Company must maintain a certain consolidated fixed charge coverage ratio. As of March 31, 2014 the Company met all covenants in that credit facility.
	At March 31, 2014, based on its performance against the most restrictive covenants listed above, the Company had the capacity to increase its borrowings by up to $87,814 under the credit facility agreement.
	The counterparty to the Company’s interest rate derivative financial instrument is Bank of the West, the Company’s primary bank. Pledged cash collateral is not required under the interest rate swap contract. At March 31, 2014, the Company
	did not hold any other derivative financial instruments. As a result, there occurs no offsetting of derivative liabilities in the Company’s financial statements. The gross amount of derivative liabilities is equal to the net amount recognized in current installments of other liabilities in the condensed consolidated balance sheets, as shown in the below table:
											Gross Amounts Not Offset in the
											Statement of Financial Position
	Description	Gross			Gross			Net Amounts			Financial			Cash			Net Amount
		Amounts of			Amounts			of Liabilities			Instruments			Collateral
		Recognized			Offset in the			Presented in						Pledged
		Liabilities			Statement			the Statement
					of Financial			of Financial
					Position			Position
	Derivatives by counterparty:
	Bank of the West	$	(428	)	$	—		$	(428	)	$	—		$	—		$	(428	)
	Total	$	(428	)	$	—		$	(428	)	$	—		$	—		$	(428	)

Reclassification

Reclassification	3 Months Ended
	Mar. 31, 2014
Reclassification	'
	9. Reclassification—Certain items may have been reclassified (if appropriate), in the prior period condensed consolidated financial statements to conform with the March 31, 2014 presentation.

Comprehensive_Income

Comprehensive Income	3 Months Ended
	Mar. 31, 2014
Comprehensive Income	'
	10. Total comprehensive income includes, in addition to net income, changes in equity that are excluded from the condensed consolidated statements of operations and are recorded directly into a separate section of stockholders’ equity on the condensed consolidated balance sheets. For the three month period ended March 31, 2014, total comprehensive income consisted of net income attributable to American Vanguard, the change in fair value of interest rate swaps and foreign currency translation adjustments.

Stock_Based_Compensation_Expen

Stock Based Compensation Expense	3 Months Ended
	Mar. 31, 2014
Stock Based Compensation Expense	'
	11. Stock Based Compensation Expense—The Company accounts for stock-based awards to employees and directors in accordance with FASB ASC 718, “Share-Based Payment,” which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees and directors including shares of common stock granted for services, employee stock options, and employee stock purchases related to the Employee Stock Purchase Plan (“employee stock purchases”) based on estimated fair values.
	Stock Options — During the three months ended March 31, 2014, the Company did not grant any employees options to acquire shares of common stock.
	Option activity within each plan is as follows:
		Incentive			Weighted Average		Exercisable
		Stock Option			Price Per Share		Weighted
		Plans					Average
							Price
							Per Share
	Balance outstanding, December 31, 2013		561,029		$	7.76	$	7.7
	Options exercised, $7.50		(82,650	)		7.5
	Balance outstanding, March 31, 2014		478,379		$	7.8	$	7.74
	Information relating to stock options at March 31, 2014 summarized by exercise price is as follows:
		Outstanding Weighted Average							Exercisable Weighted
									Average
	Exercise Price Per Share	Shares			Remaining		Exercise		Shares		Exercise
					Life		Price				Price
					(Months)
	Incentive Stock Option Plan:
	$7.50		451,700			80	$	7.5		451,700	$	7.5
	$11.32—$14.75		26,679			77	$	12.9		20,012	$	13.1
			478,379				$	7.8		471,712	$	7.74
	The weighted average exercise prices for options granted and exercisable and the weighted average remaining contractual life for options outstanding as of March 31, 2014 was as follows:
		Number			Weighted		Weighted		Intrinsic
		of			Average		Average		Value
		Shares			Exercise		Remaining		(thousands)
					Price		Contractual
							Life
							(Months)
	As of March 31, 2014:
	Incentive Stock Option Plans:
	Outstanding		478,379		$	7.8		80	$	6,625
	Expected to Vest		478,351		$	7.8		80	$	6,625
	Exercisable		471,712		$	7.74		80	$	6,563
	During the three months ended March 31, 2014 and 2013, the Company recognized stock-based compensation expense, excluding expense related to modifications, related to stock options of $11 and $209, respectively.
	As of March 31, 2014, the Company had approximately $10 of unamortized stock-based compensation expenses related to unvested stock options outstanding. This amount will be recognized over the weighted-average period of 0.2 years. This projected expense will change if any stock options are granted or cancelled prior to the respective reporting periods or if there are any changes required to be made for estimated forfeitures.
	Restricted Shares — A status summary of non-vested shares as of and for the three months ended March 31, 2014 is presented below:
		Number			Weighted
		of			Average
		Shares			Grant-
					Date
					Fair Value
	Nonvested shares at December 31, 2013		376,702		$	24.85
	Vested		(1,000	)		31.83
	Forfeited		(1,840	)		24.23
	Nonvested shares at March 31, 2014		373,862		$	24.83
	Restricted stock grants — During the three months ended March 31, 2014, the Company did not grant any shares of restricted common stock.
	During the three months ended March 31, 2013, the Company granted a total of 145,884 shares of common stock. Of these, 3,000 shares will vest one-third each year on the anniversaries of the employee’s employment date and the balance will cliff vest after three years of service. The shares granted in 2013 were average fair valued at $31.27 per share. The fair value was determined by using the publicly traded share price as of the date of grant. The Company is recognizing as expense the value of restricted shares over the required service period of three years. During the three months ended March 31, 2013, there were 8,000 restricted shares that forfeited, which had an average grant-date value of $22.17 per share.
	During the three months ended March 31, 2014 and 2013, the Company recognized stock-based compensation expense related to restricted shares of $834 and $479, respectively.
	As of March 31, 2014, the Company had approximately $4,640 of unamortized stock-based compensation expenses related to unvested restricted shares. This amount will be recognized over the weighted-average period of 1.6 years. This projected expense will change if any restricted shares are granted or cancelled prior to the respective reporting periods or if there are any changes required to be made for estimated forfeitures.
	Performance Based Shares—A status summary of non-vested performance based shares as of and for the three months ended March 31, 2014 is presented below:
		Number			Weighted
		of			Average
		Shares			Grant-
					Date
					Fair Value
	Nonvested shares at December 31, 2013		24,637		$	28.43
	Granted		—			—
	Vested		—			—
	Forfeited		—			—
	Nonvested shares at March 31, 2014		24,637		$	28.43
	Performance Based Shares — During the three months ended March 31, 2014, the Company did not grant any performance based shares.
	During 2013, the Company granted a total of 24,637 performance based shares that will cliff vest after three years of service. 80% of these performance based shares are based upon net income and net sales for the period commencing April 1, 2013 and ending December 31, 2015; the remaining 20% of performance based shares are based upon the Company’s stock price appreciation over the course of the period commencing June 6, 2013 and ending on December 31, 2015. Both parts of these awards vest in three years, but are subject to reduction to a minimum (or even zero) for meeting less than the targeted performance and to increase to a maximum of 200% for meeting in excess of the targeted performance.
	The performance based shares related to net income and net sales have an average fair value of $30.13 per share. The fair value was determined by using the publicly traded share price as of the date of grant. The performance based shares related to the Company’s stock price have an average fair value of $15.31 per share. The fair value was determined by using the Monte Carlo valuation method. For awards with performance conditions, the Company recognizes share-based compensation cost on a straight-line basis for each performance criteria over the implied service period when the Company believes it is probable that the performance targets, as defined in the agreements, will be achieved.
During the three months ended March 31, 2014, the Company recognized a reduction in stock-based compensation expense related to performance based shares of $77. There were no performance based shares issued by the Company prior to those issued during the quarter ended June 30, 2013.
As of March 31, 2014, the Company had approximately $507 of unamortized stock-based compensation expenses related to unvested performance based shares. This amount will be recognized over the weighted-average period of 2.2 years. This projected expense will change if any performance based shares are granted or cancelled prior to the respective reporting periods or if there are any changes required to be made for estimated forfeitures.

Legal_Proceedings

Legal Proceedings	3 Months Ended
	Mar. 31, 2014
Legal Proceedings	'
	12. Legal Proceedings—Summarized below are litigation matters in which there has been material activity or developments since the filing of the Company’s Form 10-K for the period ended December 31, 2013.
	A. DBCP Cases
	A number of suits have been filed against AMVAC, alleging injury from exposure to the agricultural chemical 1, 2-dibromo-3-chloropropane (“DBCP®”). DBCP was manufactured by several chemical companies, including Dow Chemical Company, Shell Oil Company and AMVAC, and was approved by the United States Environmental Protection Agency (“USEPA”) to control nematodes. DBCP was also applied on banana farms in Latin America. The USEPA suspended registrations of DBCP in October 1979, except for use on pineapples in Hawaii. The USEPA suspension was partially based on 1977 studies by other manufacturers that indicated a possible link between male fertility and exposure to DBCP among their factory production workers involved with producing the product. There are approximately 100 lawsuits, foreign and domestic, filed by former banana workers in which AMVAC has been named as a party. Fifteen of these suits have been filed in the United States (with prayers for unspecified damages) and the remainder have been filed in Nicaragua. All of these actions are in various stages and allege injury from exposure to DBCP, including claims for sterility. There have been no material developments in any of these matters since the filing of the Company’s Form 10-K for the period ended December 31, 2013 (which sets forth the procedural history of these matters in detail).
	B. Other Matters
	AMVAC has been named as one of 27 defendants in an action entitled Sanchez v. Agro Logistic Systems, Inc. et al which was filed on April 14, 2014 with the Superior Court for the State of California for the County of Los Angeles as case number BC542612. In this matter, two individuals seek unspecified damages from defendants for negligence, strict liability and other causes of action allegedly leading to physical injury (myelogenous leukemia) arising from exposure to dozens of registered products over the course of their employment as laborers from 1989 through 2012. AMVAC has not yet been served. We believe that the claims have no merit, and should we be served, we intend to defend the matter vigorously, and expect that we will enter into a joint defense arrangement with certain other defendants. At this stage in the proceedings, it is too early to determine whether a loss is probable and reasonably estimable, and the Company has not set up a reserve for this matter.
	On April 7, 2014, an action entitled Graciela Galvan v. AMVAC Chemical Corp. (naming AMVAC as the sole defendant) was filed with the Superior Court for the State of California for the County of Orange as case number 00716103CXC. The matter was subsequently served on AMVAC’s registered agent on April 18, 2014. This action involves claims by plaintiff on behalf of herself (an inactive employee currently on leave) and other “similarly situated employees” for alleged violations of wages and hours requirements under the California Labor Code. The Company believes that the claims have no merit and intends to defend the matter vigorously. At this stage in the proceedings, it is too early to determine whether a loss is probable or reasonably estimable; accordingly, the Company has not set up a reserve for the matter.

Recently_Issued_Accounting_Gui

Recently Issued Accounting Guidance	3 Months Ended
	Mar. 31, 2014
Recently Issued Accounting Guidance	'
	13. Recently Issued Accounting Guidance—In February 2013, The Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2013-02, Comprehensive Income (Topic 220): Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income, establishes new requirements for disclosing reclassifications of items out of accumulated other comprehensive income (OCI). Specifically, (1) disclosure is required of the changes in components of accumulated OCI, (2) disclosure is required of the effects on individual line items in net income for each item of accumulated OCI that is reclassified in its entirety to net income, and (3) cross references are required to other disclosures that provide additional details for OCI items that are not reclassified in their entirety to net income. The requirements of ASU 2013-02 apply to all entities (i.e., both public and nonpublic) that report items of OCI in any period presented. ASU 2013-02 is effective prospectively for reporting periods beginning after December 15, 2012. The Company adopted this standard effective January 1, 2013.

Fair_Value_of_Financial_Instru

Fair Value of Financial Instruments	3 Months Ended
	Mar. 31, 2014
Fair Value of Financial Instruments	'
	14. Fair Value of Financial Instruments—The carrying values of cash, receivables and accounts payable approximate their fair values because of the short maturity of these instruments. The fair value of the Company’s long-term debt and note payable to bank is estimated based on the quoted market prices for the same or similar issues or on the current rates offered to the Company for debt of the same remaining maturities. Such fair value approximates the respective carrying values of the Company’s long-term debt and note payable to bank.
	The Company’s cash flow hedge related to a variable debt instrument is measured at fair value on a recurring basis, and the balances as of March 31, 2014 and December 31, 2013 (which are included in other liabilities in the condensed consolidated balance sheets) were as follows:
			Fair Value Measurements
			Using Input Type
			Level 1		Level 2		Level 3
	As of March 31, 2014:
	Liability:
	Interest rate derivative financial instrument (1)		$	—	$	428	$	—
	As of December 31, 2013:
	Liability:
	Interest rate derivative financial instrument (1)		$	—	$	564	$	—
	-1	Includes accrued interest expense
	The valuation techniques used to measure the fair value of the derivative financial instruments above in which the counterparties have high credit ratings, were derived from pricing models, such as discounted cash flow techniques, with all significant inputs derived from or corroborated by observable market data. The Company’s discounted cash flow techniques use observable market inputs, such as LIBOR-based yield curves and foreign currency forward rates.

Accumulated_Other_Comprehensiv

Accumulated Other Comprehensive Income	3 Months Ended
	Mar. 31, 2014
Accumulated Other Comprehensive Income	'
	15. Accumulated Other Comprehensive Income -
	The following table lists the beginning balance, annual activity and ending balance of each component of accumulated other comprehensive loss:
		Interest			FX			Total
		Rate			Translation
		Swap
	Balance, December 31, 2013	$	(340	)	$	(708	)	$	(1,048	)
	Other comprehensive income/(loss) before reclassifications		(23	)		51			28
	Amounts reclassified from AOCI		159			—			159
	Balance, March 31, 2014	$	(204	)	$	(657	)	$	(861	)

Equity_Investment

Equity Investment	3 Months Ended
	Mar. 31, 2014
Equity Investment	'
	16. On March 25, 2013, the Company made a $3,687 equity investment in TyraTech Inc. (“TyraTech”), a Delaware corporation that specializes in developing, marketing and selling pesticide products containing essential oils and other natural ingredients, to acquire an ownership position of approximately 29.27%. In February 2014, TyraTech issued 37,391,763 shares and raised approximately £1.87 ($3.1) million. Due to the share issuance, the Company recognized a $256 gain from the dilution of the Company’s ownership position. Following the issuance of these new shares, as of March 31, 2014, the Company’s ownership position in TyraTech was approximately 23.96%. The Company utilizes the equity method of accounting with respect to this investment. As a result, our net income includes losses from equity method investments, which represents our proportionate share of TyraTech’s estimated net losses for the current accounting period. For the three months ended March 31, 2014, the Company recognized an operating loss of $328 as a result of the Company’s ownership position in TyraTech.
	The Company’s investment in TyraTech is included in other assets on the balance sheet. At March 31, 2014, the carrying value of the Company’s investment in TyraTech was $2,629 and the quoted market value of its shareholding was $9,550 based on the London Stock Exchange, Alternative Investment Market (“AIM”).

Income_Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2014
Income Taxes	'
	17. Income Taxes – Income tax expense was $1,016 for the three months ended March 31, 2014 as compared to $8,981 for the three months ended March 31, 2013. The effective tax rate was 30.0% in 2014 and 34.8% in 2013.
	The effective tax rate for the three months ended March 31, 2014 is based on the projected income for the full year and is subject to ongoing review and adjustment by management.

Property_plant_and_equipment_T

Property, plant and equipment (Tables)	3 Months Ended
	Mar. 31, 2014
Summary of Property, Plant and Equipment	'
	Property, plant and equipment at March 31, 2014 and December 31, 2013 consists of the following:
		March 31,			December 31,
		2014			2013
	Land	$	2,458		$	2,458
	Buildings and improvements		14,237			14,167
	Machinery and equipment		97,124			94,184
	Office furniture, fixtures and equipment		9,932			9,717
	Automotive equipment		288			278
	Construction in progress		9,196			10,615
			133,235			131,419
	Less accumulated depreciation		(81,087	)		(78,951	)
		$	52,148		$	52,468

Inventories_Tables

Inventories (Tables)	3 Months Ended
	Mar. 31, 2014
Components of Inventories	'
	The components of inventories consist of the following:
		March 31,		December 31,
		2014		2013
	Finished products	$	144,450	$	126,872
	Raw materials		14,009		12,958
		$	158,459	$	139,830

Segment_Reporting_Tables

Segment Reporting (Tables)	3 Months Ended
	Mar. 31, 2014
Summary of Business Sales Segmentation as per Product	'
	Selective enterprise information is as follows:
		Three Months Ended
		March 31
		2014		2013
	Net sales:
	Insecticides	$	46,437	$	78,867
	Herbicides/soil fumigants/fungicides		22,931		32,986
	Other, including plant growth regulators		3,807		3,691
			73,175		115,544
	Non-crop		7,920		5,993
		$	81,095	$	121,537
Summary of Business Sales Segmentation as per Location	'
		Three Months Ended
		March 31
		2014		2013
	Net sales:
	US sales	$	57,956	$	103,105
	International sales		23,139		18,432
		$	81,095	$	121,537

Earnings_Per_Share_Tables

Earnings Per Share (Tables)	3 Months Ended
	Mar. 31, 2014
Components of Basic and Diluted Earnings Per Share	'
	The components of basic and diluted earnings per share were as follows:
		Three Months Ended
		March 31,
		2014		2013
	Numerator:
	Net income attributable to American Vanguard	$	2,159	$	16,915
	Denominator:
	Weighted averages shares outstanding-basic		28,401		28,269
	Dilutive effect of stock options and grants		487		610
			28,888		28,879

Indebtedness_Tables

Indebtedness (Tables)	3 Months Ended
	Mar. 31, 2014
Summary of Short-Term and Long-Term Loan Balances in Condensed Consolidated Balance Sheets	'
	The Company has a revolving line of credit and various notes payable that together constitute the short-term and long-term loan balances shown in the condensed consolidated balance sheets at March 31, 2014 and December 31, 2013. These are summarized in the following table:
	Indebtedness	March 31, 2014									December 31, 2013
	$000’s	Long-			Short-			Total			Long-			Short-			Total
		term			term						term			term
	Revolving line of credit	$	99,000		$	—		$	99,000		$	51,550		$	—		$	51,550
	Notes payable		108			70			178			126			69			195
	Total Indebtedness	$	99,108		$	70		$	99,178		$	51,676		$	69		$	51,745
Summary of Effect of Derivative Instruments on Statement of Financial Performance	'
	The following tables illustrate the impact of derivatives on the Company’s statement of operations for the quarter ended March 31, 2014.
	The Effect of Derivative Instruments on the Statement of Financial Performance
	For the Period Ended March 31
	Derivatives in ASC 815 Cash Flow	Amount of Gain or						Location of Gain or			Amount of Gain or (Loss)						Location of Gain or		Amount of Gain or
	Hedging Relationships	(Loss) Recognized in						(Loss) Reclassified			Reclassified from Accumulated						(Loss) Recognized in		(Loss)
		OCI on Derivative						from Accumulated			OCI into Income (Effective						Income on Derivative		Recognized
		(Effective Portion)						OCI into Income			Portion)						(Ineffective Portion)		in Income on
								(Effective Portion)											Derivative
																			(Ineffective Portion)
		2014			2013						2014			2013					2014		2013
	Interest rate contracts	$	(23	)	$	(7	)		Interest Expense		$	(159	)	$	(185	)	Interest Expense		$	—	$	—
	Total	$	(23	)	$	(7	)				$	(159	)	$	(185	)			$	—	$	—
Derivative Liabilities Recognized In Current Installments of Other Liabilities in Condensed Consolidated Balance Sheets	'
	The gross amount of derivative liabilities is equal to the net amount recognized in current installments of other liabilities in the condensed consolidated balance sheets, as shown in the below table:
											Gross Amounts Not Offset in the
											Statement of Financial Position
	Description	Gross			Gross			Net Amounts			Financial			Cash			Net Amount
		Amounts of			Amounts			of Liabilities			Instruments			Collateral
		Recognized			Offset in the			Presented in						Pledged
		Liabilities			Statement			the Statement
					of Financial			of Financial
					Position			Position
	Derivatives by counterparty:
	Bank of the West	$	(428	)	$	—		$	(428	)	$	—		$	—		$	(428	)
	Total	$	(428	)	$	—		$	(428	)	$	—		$	—		$	(428	)

Stock_Based_Compensation_Expen1

Stock Based Compensation Expense (Tables)	3 Months Ended
	Mar. 31, 2014
Summary of Option Activity	'
	Option activity within each plan is as follows:
		Incentive			Weighted Average		Exercisable
		Stock Option			Price Per Share		Weighted
		Plans					Average
							Price
							Per Share
	Balance outstanding, December 31, 2013		561,029		$	7.76	$	7.7
	Options exercised, $7.50		(82,650	)		7.5
	Balance outstanding, March 31, 2014		478,379		$	7.8	$	7.74
Summary of Stock Options Summarized by Exercise Price	'
	Information relating to stock options at March 31, 2014 summarized by exercise price is as follows:
		Outstanding Weighted Average							Exercisable Weighted
									Average
	Exercise Price Per Share	Shares			Remaining		Exercise		Shares		Exercise
					Life		Price				Price
					(Months)
	Incentive Stock Option Plan:
	$7.50		451,700			80	$	7.5		451,700	$	7.5
	$11.32—$14.75		26,679			77	$	12.9		20,012	$	13.1
			478,379				$	7.8		471,712	$	7.74
Weighted Average Exercise Prices for Options Granted and Exercisable and Weighted Average Remaining Contractual Life for Options Outstanding	'
	The weighted average exercise prices for options granted and exercisable and the weighted average remaining contractual life for options outstanding as of March 31, 2014 was as follows:
		Number			Weighted		Weighted		Intrinsic
		of			Average		Average		Value
		Shares			Exercise		Remaining		(thousands)
					Price		Contractual
							Life
							(Months)
	As of March 31, 2014:
	Incentive Stock Option Plans:
	Outstanding		478,379		$	7.8		80	$	6,625
	Expected to Vest		478,351		$	7.8		80	$	6,625
	Exercisable		471,712		$	7.74		80	$	6,563
Summary of Non-Vested Shares	'
	Restricted Shares — A status summary of non-vested shares as of and for the three months ended March 31, 2014 is presented below:
		Number			Weighted
		of			Average
		Shares			Grant-
					Date
					Fair Value
	Nonvested shares at December 31, 2013		376,702		$	24.85
	Vested		(1,000	)		31.83
	Forfeited		(1,840	)		24.23
	Nonvested shares at March 31, 2014		373,862		$	24.83
Performance Shares	'
Summary of Non-Vested Shares	'
	Performance Based Shares—A status summary of non-vested performance based shares as of and for the three months ended March 31, 2014 is presented below:
		Number			Weighted
		of			Average
		Shares			Grant-
					Date
					Fair Value
	Nonvested shares at December 31, 2013		24,637		$	28.43
	Granted		—			—
	Vested		—			—
	Forfeited		—			—
	Nonvested shares at March 31, 2014		24,637		$	28.43

Fair_Value_of_Financial_Instru1

Fair Value of Financial Instruments (Tables)	3 Months Ended
	Mar. 31, 2014
Cash Flow Hedge Related to Variable Debt Instrument and Outstanding Foreign Currency Derivatives to Hedge Foreign Currency Balances Measured at Fair Value on Recurring Basis, and Balances	'
	The Company’s cash flow hedge related to a variable debt instrument is measured at fair value on a recurring basis, and the balances as of March 31, 2014 and December 31, 2013 (which are included in other liabilities in the condensed consolidated balance sheets) were as follows:
			Fair Value Measurements
			Using Input Type
			Level 1		Level 2		Level 3
	As of March 31, 2014:
	Liability:
	Interest rate derivative financial instrument (1)		$	—	$	428	$	—
	As of December 31, 2013:
	Liability:
	Interest rate derivative financial instrument (1)		$	—	$	564	$	—
	-1	Includes accrued interest expense

Accumulated_Other_Comprehensiv1

Accumulated Other Comprehensive Income (Tables)	3 Months Ended
	Mar. 31, 2014
Beginning Balance, Annual Activity and Ending Balance of each Component of Accumulated Other Comprehensive loss	'
	The following table lists the beginning balance, annual activity and ending balance of each component of accumulated other comprehensive loss:
		Interest			FX			Total
		Rate			Translation
		Swap
	Balance, December 31, 2013	$	(340	)	$	(708	)	$	(1,048	)
	Other comprehensive income/(loss) before reclassifications		(23	)		51			28
	Amounts reclassified from AOCI		159			—			159
	Balance, March 31, 2014	$	(204	)	$	(657	)	$	(861	)

Summary_of_Property_Plant_and_

Summary of Property, Plant and Equipment (Detail) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, Gross	$133,235	$131,419
Less accumulated depreciation	-81,087	-78,951
Total Property, plant and equipment	52,148	52,468
Land	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, Gross	2,458	2,458
Buildings and improvements	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, Gross	14,237	14,167
Machinery and equipment	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, Gross	97,124	94,184
Office furniture, fixtures and equipment	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, Gross	9,932	9,717
Automotive equipment	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, Gross	288	278
Construction in progress	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, Gross	$9,196	$10,615

Components_of_Inventories_Deta

Components of Inventories (Detail) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Inventory [Line Items]	'	'
Finished products	$144,450	$126,872
Raw materials	14,009	12,958
Total Inventories	$158,459	$139,830

Segment_Reporting_Additional_I

Segment Reporting - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2014
	Segment
Business reportable segment	1

Summary_of_Business_Sales_Segm

Summary of Business Sales Segmentation as per Product (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Net Sales:	'	'
Total Crop	$73,175	$115,544
Non-crop	7,920	5,993
Total Sales	81,095	121,537
Insecticides	'	'
Net Sales:	'	'
Total Crop	46,437	78,867
Herbicides/Soil Fumigants/Fungicides	'	'
Net Sales:	'	'
Total Crop	22,931	32,986
Other, Including Plant Growth Regulators	'	'
Net Sales:	'	'
Total Crop	$3,807	$3,691

Summary_of_Business_Sales_Segm1

Summary of Business Sales Segmentation as per Location (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Net Sales:	'	'
Total Sales	$81,095	$121,537
US	'	'
Net Sales:	'	'
Total Sales	57,956	103,105
International	'	'
Net Sales:	'	'
Total Sales	$23,139	$18,432

Cash_Dividends_Additional_Info

Cash Dividends - Additional Information (Detail) (USD $)	1 Months Ended			0 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 10, 2014	Apr. 19, 2013	Mar. 11, 2013	Apr. 18, 2014
				Subsequent Event
Dividends [Line Items]	'	'	'	'
Cash dividend declared	$0.05	'	$0.07	'
Dividend distributed date	18-Apr-14	'	19-Apr-13	'
Cash dividend record date	4-Apr-14	'	5-Apr-13	'
Cash dividends paid	'	$1,976	'	$1,417

Components_of_Basic_and_Dilute

Components of Basic and Diluted Earnings Per Share (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Numerator:	'	'
Net income attributable to American Vanguard	$2,159	$16,915
Denominator:	'	'
Weighted averages shares outstanding-basic	28,401	28,269
Dilutive effect of stock options and grants	487	610
Weighted average shares outstanding - assuming dilution	28,888	28,879

Summary_Revolving_Line_of_Cred

Summary Revolving Line of Credit And Various Notes Payable Constitute Short-Term and Long-Term Loan Balances Together (Detail) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Extinguishment of Debt [Line Items]	'	'
Long Term debt	$99,108	$51,676
Short-term	70	69
Total indebtedness	99,178	51,745
Revolving line of credit	'	'
Extinguishment of Debt [Line Items]	'	'
Long Term debt	99,000	51,550
Total indebtedness	99,000	51,550
Notes payable	'	'
Extinguishment of Debt [Line Items]	'	'
Long Term debt	108	126
Short-term	70	69
Total indebtedness	$178	$195

Indebtedness_Additional_Inform

Indebtedness - Additional Information (Detail) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
	Contract
Debt [Line Items]	'	'
Number of Interest rate swap contract outstanding	1	'
Losses in other comprehensive income expected to be reclassified to earnings	($204,000)	'
Duration of losses in other comprehensive income expected to be reclassified to earnings	'12 months	'
Fixed interest rate for interest rate swap contract	3.39%	3.39%
Interest rate swap, start date	30-Mar-11	'
Interest rate swap, termination date	31-Dec-14	'
Maximum	'	'
Debt [Line Items]	'	'
Capacity to increase borrowings under credit agreement	87,814,000	'
Cash Flow Hedging | Interest Rate Swap	'	'
Debt [Line Items]	'	'
Notional amount of interest rate swap	34,875,000	'
Revolving Credit Facility	'	'
Debt [Line Items]	'	'
Senior secured credit facility	200,000,000	'
Senior secured credit facility term	'5 years	'
Revolving Credit Facility | Accordion Feature	'	'
Debt [Line Items]	'	'
Senior secured credit facility	$100,000,000	'

Summary_of_Effect_of_Derivativ

Summary of Effect of Derivative Instruments on Statement of Financial Performance (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Derivative Instruments, Gain (Loss) [Line Items]	'	'
Amount of Gain or (Loss) Recognized in OCI on Derivative (Effective Portion)	($23)	($7)
Amount of Gain or (Loss) Reclassified from Accumulated OCI into Income (Effective Portion)	-159	-185
Amount of Gain or (Loss) Recognized in Income on Derivative (Ineffective Portion)	'	'
Designated as Hedging | Cash Flow Hedging | Interest Rate Contracts	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'
Amount of Gain or (Loss) Recognized in OCI on Derivative (Effective Portion)	-23	-7
Designated as Hedging | Cash Flow Hedging | Interest Rate Contracts | Interest Expense	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'
Amount of Gain or (Loss) Reclassified from Accumulated OCI into Income (Effective Portion)	-159	-185
Amount of Gain or (Loss) Recognized in Income on Derivative (Ineffective Portion)	'	'

Derivative_Liabilities_Recogni

Derivative Liabilities Recognized in Current Installments of Other Liabilities in Condensed Consolidated Balance Sheets (Detail) (USD $)	Mar. 31, 2014
In Thousands, unless otherwise specified
Derivatives, Fair Value [Line Items]	'
Gross Amounts of Recognized Liabilities	($428)
Gross Amounts Offset in the Statement of Financial Position	'
Net Amounts of Liabilities Presented in the Statement of Financial Position	-428
Financial Instruments	'
Cash Collateral Pledged	'
Net Amount	-428
Bank of the West	'
Derivatives, Fair Value [Line Items]	'
Gross Amounts of Recognized Liabilities	-428
Gross Amounts Offset in the Statement of Financial Position	'
Net Amounts of Liabilities Presented in the Statement of Financial Position	-428
Financial Instruments	'
Cash Collateral Pledged	'
Net Amount	($428)

Summary_of_Option_Activity_Det

Summary of Option Activity (Detail) (USD $)	3 Months Ended
	Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Incentive Stock Option Plans, Beginning balance	561,029
Incentive Stock Option Plans, Option exercised	-82,650
Incentive Stock Option Plans, Ending balance	478,379
Weighted Average Price Per Share, Beginning balance	$7.76
Weighted Average Price Per Share, Option exercised	$7.50
Weighted Average Price Per Share, Ending balance	$7.80
Exercisable Weighted Average Price Per Share, Beginning balance	$7.70
Exercisable Weighted Average Price Per Share, Ending balance	$7.74

Summary_of_Option_Activity_Par

Summary of Option Activity (Parenthetical) (Detail) (USD $)	3 Months Ended
	Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Options exercised, Lower Range	$7.50

Summary_of_Stock_Options_Summa

Summary of Stock Options Summarized by Exercise Price (Detail) (USD $)	3 Months Ended
	Mar. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Options exercised, Lower Range	$7.50	'
Outstanding Weighted Average, Exercise Price	$7.80	$7.76
Exercisable Weighted Average, Exercise Price	$7.74	$7.70
Incentive Stock Option Plan	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Outstanding Weighted Average, Shares	478,379	'
Outstanding Weighted Average, Remaining Life (Months)	'80 months	'
Outstanding Weighted Average, Exercise Price	$7.80	'
Exercisable Weighted Average, Shares	471,712	'
Exercisable Weighted Average, Exercise Price	$7.74	'
Incentive Stock Option Plan | Range One	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Options exercised, Lower Range	$7.50	'
Outstanding Weighted Average, Shares	451,700	'
Outstanding Weighted Average, Remaining Life (Months)	'80 months	'
Outstanding Weighted Average, Exercise Price	$7.50	'
Exercisable Weighted Average, Shares	451,700	'
Exercisable Weighted Average, Exercise Price	$7.50	'
Incentive Stock Option Plan | Range Two	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Options exercised, Lower Range	$11.32	'
Options exercised, Upper Range	$14.75	'
Outstanding Weighted Average, Shares	26,679	'
Outstanding Weighted Average, Remaining Life (Months)	'77 months	'
Outstanding Weighted Average, Exercise Price	$12.90	'
Exercisable Weighted Average, Shares	20,012	'
Exercisable Weighted Average, Exercise Price	$13.10	'

Weighted_Average_Exercise_Pric

Weighted Average Exercise Prices for Options Granted and Exercisable and Weighted Average Remaining Contractual Life for Options Outstanding (Detail) (USD $)	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2014
In Thousands, except Share data, unless otherwise specified			Incentive Stock Option Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Number of Shares, Outstanding	'	'	478,379
Number of Shares, Expected to Vest	'	'	478,351
Number of Shares, Exercisable	'	'	471,712
Weighted Average Exercise Price, Outstanding	$7.80	$7.76	$7.80
Weighted Average Exercise Price, Expected to Vest	'	'	$7.80
Weighted Average Exercisable, Exercise Price	$7.74	$7.70	$7.74
Weighted Average Remaining Life, Outstanding	'	'	'80 months
Weighted Average Remaining Contractual Life, Expected to Vest	'	'	'80 months
Weighted Average Remaining Contractual Life, Exercisable	'	'	'80 months
Intrinsic Value, Outstanding	'	'	$6,625
Intrinsic Value, Expected to Vest	'	'	6,625
Intrinsic Value, Exercisable	'	'	$6,563

Stock_Based_Compensation_Expen2

Stock Based Compensation Expense - Additional Information (Detail) (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Stock Options	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Stock-based compensation expense	$11	$209
Nonvested unamortized stock-based compensation expense, value	10	'
Nonvested unamortized stock-based compensation expense, contractual term	'2 months 12 days	'
Restricted Stock	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Stock-based compensation expense	834	479
Nonvested unamortized stock-based compensation expense, value	4,640	'
Nonvested unamortized stock-based compensation expense, contractual term	'1 year 7 months 6 days	'
Number of Shares, Granted	'	145,884
Number of shares vested	1,000	'
Weighted Average Grant-Date Fair Value, Granted	'	$31.27
Number of Shares, Forfeited	1,840	8,000
Weighted Average Grant-Date Fair Value, Forfeited	$24.23	$22.17
Restricted Stock | Vest one-third each year	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Number of shares vested	'	3,000
Restricted Stock | Cliff Vest After Three Years	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Expenses recognized period	'	'3 years
Performance Shares	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Stock-based compensation expense	($77)	'
Nonvested unamortized stock-based compensation expense, contractual term	'2 years 2 months 12 days	'
Number of Shares, Granted	'	24,637
Number of shares vested	'	'
Expenses recognized period	'	'3 years
Weighted Average Grant-Date Fair Value, Granted	'	'
Number of Shares, Forfeited	'	'
Weighted Average Grant-Date Fair Value, Forfeited	'	'
Targeted performance percentage	'	200.00%
Performance Shares | Performance based shares based upon net income and net sales for the period commencing April 1, 2013 and ending December 31, 2015	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Weighted Average Grant-Date Fair Value, Granted	$30.13	'
Percentage of shares vesting based on Performance	'	80.00%
Performance Shares | Performance based shares based upon AVD stock price appreciation over the course of the period commencing June 6, 2013 and ending on December 31, 2015	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Weighted Average Grant-Date Fair Value, Granted	$15.31	'
Percentage of shares vesting based on Performance	'	20.00%

Summary_of_NonVested_Shares_De

Summary of Non-Vested Shares (Detail) (Restricted Stock, USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Restricted Stock	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Number of Shares, Beginning balance	376,702	'
Number of Shares, Vested	-1,000	'
Number of Shares, Forfeited	-1,840	-8,000
Number of Shares, Ending Balance	373,862	'
Weighted Average Grant-Date Fair Value, Beginning balance	$24.85	'
Weighted Average Grant-Date Fair Value, Vested	$31.83	'
Weighted Average Grant-Date Fair Value, Forfeited	$24.23	$22.17
Weighted Average Grant-Date Fair Value, Ending balance	$24.83	'

Status_Summary_of_NonVested_Sh

Status Summary of Non-Vested Shares (Detail) (Performance Shares, USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Performance Shares	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Number of Shares, Beginning balance	24,637	'
Number of Shares, Granted	'	24,637
Number of Shares, Vested	'	'
Number of Shares, Forfeited	'	'
Number of Shares, Ending Balance	24,637	'
Weighted Average Grant-Date Fair Value, Beginning balance	$28.43	'
Weighted Average Grant-Date Fair Value, Granted	'	'
Weighted Average Grant-Date Fair Value, Vested	'	'
Weighted Average Grant-Date Fair Value, Forfeited	'	'
Weighted Average Grant-Date Fair Value, Ending balance	$28.43	'

Stock_Options_Additional_Infor

Stock Options - Additional Information (Detail) (Performance Shares, USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014
Performance Shares	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Unamortized stock-based compensation expense	$507
Nonvested unamortized stock-based compensation expense, contractual term	'2 years 2 months 12 days

Legal_Proceedings_Additional_I

Legal Proceedings - Additional Information (Detail)	1 Months Ended		3 Months Ended
	Apr. 14, 2014	Apr. 07, 2014	Mar. 31, 2014
	Subsequent Event	Subsequent Event	Former Banana Workers
	Sanchez V. Agro Logistic Systems, Inc.	Graciela Galvan V AMVAC Chemical Corp	Case
	Defendant
Loss Contingencies [Line Items]	'	'	'
Number of lawsuits filed	'	'	100
Lawsuits filed in United States	'	'	15
Number of defendants	27	'	'
Company actions	'We believe that the claims have no merit, and should we be served, we intend to defend the matter vigorously, and expect that we will enter into a joint defense arrangement with certain other defendants.	'The Company believes that the claims have no merit and intends to defend the matter vigorously.	'
Law suit filing date	'	'April 7, 2014	'
Laws affected	'	'This action involves claims by plaintiff on behalf of herself (an inactive employee currently on leave) and other "similarly situated employees" for alleged violations of wages and hours requirements under the California Labor Code.	'

Cash_Flow_Hedge_Related_to_Var

Cash Flow Hedge Related to Variable Debt Instrument and Outstanding Foreign Currency Derivatives to Hedge Foreign Currency Balances Measured at Fair Value on Recurring Basis, and Balances (Detail) (Fair Value, Measurements, Recurring, Cash Flow Hedging, Level 2, USD $)	Mar. 31, 2014		Dec. 31, 2013
In Thousands, unless otherwise specified
Fair Value, Measurements, Recurring | Cash Flow Hedging | Level 2	'		'
Liability:	'		'
Interest rate derivative financial instrument	$428	[1]	$564	[1]
[1]	Includes accrued interest expense

Beginning_Balance_Annual_Activ

Beginning Balance, Annual Activity and Ending Balance of each Component of Accumulated Other Comprehensive Loss (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014
Accumulated Other Comprehensive Income (Loss) [Line Items]	'
Beginning Balance	($1,048)
Other comprehensive income/(loss) before reclassifications	28
Amounts reclassified from AOCI	159
Ending Balance	-861
Interest Rate Swap	'
Accumulated Other Comprehensive Income (Loss) [Line Items]	'
Beginning Balance	-340
Other comprehensive income/(loss) before reclassifications	-23
Amounts reclassified from AOCI	159
Ending Balance	-204
Accumulated Translation Adjustment	'
Accumulated Other Comprehensive Income (Loss) [Line Items]	'
Beginning Balance	-708
Other comprehensive income/(loss) before reclassifications	51
Ending Balance	($657)

Equity_Investment_Additional_I

Equity Investment - Additional Information (Detail)	1 Months Ended		3 Months Ended		1 Months Ended
In Thousands, except Share data, unless otherwise specified	Feb. 28, 2014	Mar. 25, 2013	Mar. 31, 2014	Mar. 31, 2013	Feb. 28, 2014	Feb. 28, 2014
	USD ($)	USD ($)	USD ($)	USD ($)	TyraTech Inc.	TyraTech Inc.
					USD ($)	GBP (£)
Equity Method Investments [Line Items]	'	'	'	'	'	'
Equity investment	'	$3,687	'	$3,687	'	'
Equity investment ownership position	'	29.27%	23.96%	'	'	'
Shares issued by equity investee	'	'	'	'	37,391,763	37,391,763
Amount raised by equity investee on shares issued	'	'	1,018	427	3,100	1,870
Gain from the dilution of the ownership position	256	'	256	'	'	'
Loss from equity method investment	'	'	328	'	'	'
Carrying value of equity investment	'	'	2,629	'	'	'
Quoted market value of equity investment	'	'	$9,550	'	'	'

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Income Taxes [Line Items]	'	'
Income tax expense	$1,016	$8,981
Effective tax rate	30.00%	34.80%